Sanofi moved into its new global headquarters in Paris, the company announced Monday morning.

La Maison Sanofi, the 9,000sqm site, will house 500 employees and is located in the 17th arrondissement of Paris, at 46-48 Avenue de la Grande Armée.

Plans for the “substantial office complex” were first announced in late 2020, when private investment house Ardian stated that Sanofi would lease space in the two interconnected six- and eight-story buildings that the company purchased in the summer of 2018.

Sanofi said the two buildings have been merged into one through the work of renowned architect Franklin Azzi. 

The French pharma giant said that each employee’s carbon footprint has been reduced by about 100% compared to the previous site. 

At a time when companies are struggling to get workers back in the office following the popularization of remote work during the COVID-19 pandemic, Sanofi has doubled down on its workplaces worldwide. Employees will be able to use an app to schedule their remote days or check into the office while also accessing their locker, booking a room for catering services while on-site.

The company has also opened or renovated its Cambridge Crossing site near Boston, the Gentilly Campus in the Paris region and the Carteret Campus in Lyon, France.

“The opening of La Maison Sanofi is another step toward the modern healthcare company we strive to become,” Sanofi CEO Paul Hudson said in a statement. “A company open to the world and that seeks to offer its people the best work environment to chase the miracles of science.”

Sanofi announced the opening of the new office weeks after signing a research collaboration agreement worth up to $1.2 billion with Insilico Medicine, a clinical stage artificial intelligence-driven drug discovery company. As part of the deal, the French drugmaker will pay Insilico up to $21.5 million upfront and receive access to the company’s scientific team to “identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage.”

Additionally, Sanofi recently released its latest earnings report, highlighted by sales growth of 9% at CER thanks to its Specialty Care and Vaccines portfolios. Its General Medicines segment also reported 2.4% core assets growth despite lower than expected Lovenox sales.